SCHEDULE: Baker Bros. Advisors Boosts Immatics N.V. Stake to 8.4%

Baker Bros. Advisors and its affiliates have increased their beneficial ownership in Immatics N.V. to 8.4% of outstanding ordinary shares.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker (collectively, the "Reporting Persons") have filed an Amendment No. 4 to their Schedule 13G for Immatics N.V.
• The Reporting Persons beneficially own an aggregate of 10,168,901 ordinary shares of Immatics N.V.
• This represents 8.4% of the outstanding ordinary shares of Immatics N.V.
• The ownership percentage is calculated based on 121,550,169 shares outstanding as of March 31, 2025, as reported by Immatics N.V. in its 6-K filing on May 13, 2025.
• The shares are held by Baker Brothers Life Sciences, L.P. (9,354,564 shares or 7.7%) and 667, L.P. (814,337 shares or 0.7%).
• The acquisition and holding of these securities are stated to be in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant, continued stake by a prominent biotech investor, Baker Bros. Advisors, which can be interpreted as a vote of confidence in Immatics N.V. The stated purpose of the investment is passive, suggesting a long-term view rather than an activist stance. This is generally a positive signal for the company's stability and investor perception.

Positives

• Increased stake by a prominent biotech investor group, Baker Bros. Advisors, may signal confidence in Immatics N.V.'s long-term prospects.
• The investment is stated to be for ordinary course of business, not for control, suggesting a passive, long-term investment strategy.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Immatics N.V.'s future performance or strategic outlook.

Management Comments

• The filing does not contain direct quotes or paraphrased statements from Immatics N.V. management. It includes a certification from the Reporting Persons that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

This filing indicates continued or increased investment by a specialized biotech investment firm, Baker Bros. Advisors, in Immatics N.V., a company focused on T-cell receptor (TCR) therapeutics. Such investments by dedicated life sciences funds often reflect a positive long-term view on the company's pipeline and market potential within the competitive biotechnology sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a reputable institutional investor like Baker Bros. Advisors may enhance investor confidence and potentially influence market perception positively.
• Company Management: The filing clarifies that the stake is not for control purposes, which may reduce concerns about activist pressure from this investor group.

Key Dates

Recommendation

The filing indicates a substantial and continued stake by Baker Bros. Advisors, a well-regarded biotech investor, which suggests a positive long-term view on Immatics N.V. However, as a Schedule 13G, it provides no new operational or financial performance data to warrant a 'buy' recommendation. The 'hold' recommendation reflects the stability implied by a major investor maintaining a significant position, without new catalysts for a strong upward move based solely on this filing.

Keywords

Immatics N.V., Baker Bros. Advisors, Schedule 13G, Beneficial Ownership, Biotechnology, Healthcare Investment, Institutional Investor, IMTX